24 results on '"Lubiński, Jan"'
Search Results
2. CHEK2 mutations and the risk of papillary thyroid cancer
- Author
-
Siołek, Monika, Cybulski, Cezary, Gąsior-Perczak, Danuta, Kowalik, Artur, Kozak-Klonowska, Beata, Kowalska, Aldona, Chłopek, Małgorzata, Kluźniak, Wojciech, Wokołorczyk, Dominika, Pałyga, Iwona, Walczyk, Agnieszka, Lizis-Kolus, Katarzyna, Sun, Ping, Lubiński, Jan, Narod, Steven A., and Góźdż, Stanisław
- Published
- 2015
- Full Text
- View/download PDF
3. Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions
- Author
-
Barrett, Jennifer H., Taylor, John C., Bright, Chloe, Harland, Mark, Dunning, Alison M., Akslen, Lars A., Andresen, Per A., Avril, Marie-Françoise, Azizi, Esther, Bianchi Scarrà, Giovanna, Brossard, Myriam, Brown, Kevin M., Dębniak, Tadeusz, Elder, David E., Friedman, Eitan, Ghiorzo, Paola, Gillanders, Elizabeth M., Gruis, Nelleke A., Hansson, Johan, Helsing, Per, Hočevar, Marko, Höiom, Veronica, Ingvar, Christian, Landi, Maria Teresa, Lang, Julie, Lathrop, Mark G., Lubiński, Jan, Mackie, Rona M., Molven, Anders, Novaković, Srdjan, Olsson, Håkan, Puig, Susana, Puig-Butille, Joan Anton, van der Stoep, Nienke, van Doorn, Remco, van Workum, Wilbert, Goldstein, Alisa M., Kanetsky, Peter A., Pharoah, Paul D. P., Demenais, Florence, Hayward, Nicholas K., Newton Bishop, Julia A., Bishop, Timothy D., and Iles, Mark M.
- Published
- 2015
- Full Text
- View/download PDF
4. The presence of prostate cancer at biopsy is predicted by a number of genetic variants
- Author
-
Kashyap, Aniruddh, Kluźniak, Wojciech, Wokołorczyk, Dominika, Gołąb, Adam, Sikorski, Andrzej, Słojewski, Marcin, Gliniewicz, Bartłomiej, Świtała, Jerzy, Borkowski, Tomasz, Borkowski, Andrzej, Antczak, Andrzej, Wojnar, Łukasz, Przybyła, Jacek, Sosnowski, Marek, Małkiewicz, Bartosz, Zdrojowy, Romuald, Sikorska-Radek, Paulina, Matych, Józef, Wilkosz, Jacek, Różański, Waldemar, Kiś, Jacek, Bar, Krzysztof, Bryniarski, Piotr, Paradysz, Andrzej, Jersak, Konrad, Niemirowicz, Jerzy, Słupski, Piotr, Jarzemski, Piotr, Skrzypczyk, Michał, Dobruch, Jakub, Domagała, Paweł, Piotrowski, Krzysztof, Jakubowska, Anna, Gronwald, Jacek, Huzarski, Tomasz, Byrski, Tomasz, Dębniak, Tadeusz, Górski, Bohdan, Masojć, Bartłomiej, van de Wetering, Thierry, Menkiszak, Janusz, Akbari, Mohammad R., Lubiński, Jan, Narod, Steven A., and Cybulski, Cezary
- Published
- 2014
- Full Text
- View/download PDF
5. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer
- Author
-
Notaridou, Maria, Quaye, Lydia, Dafou, Dimitra, Jones, Chris, Song, Honglin, Hgdall, Estrid, Kjaer, Susanne K., Christensen, Lise, Hgdall, Claus, Blaakaer, Jan, McGuire, Valerie, Wu, Anna H., Van Den Berg, David J., Pike, Malcolm C., Gentry-Maharaj, Aleksandra, Wozniak, Eva, Sher, Tanya, Jacobs, Ian J., Tyrer, Jonathan, Schildkraut, Joellen M., Moorman, Patricia G., Iversen, Edwin S., Jakubowska, Anna, Mędrek, Krzysztof, Lubiński, Jan, Ness, Roberta B., Moysich, Kirsten B., Lurie, Galina, Wilkens, Lynne R., Carney, Michael E., Wang-Gohrke, Shan, Doherty, Jennifer A., Rossing, Mary Anne, Beckmann, Matthias W., Thiel, Falk C., Ekici, Arif B., Chen, Xiaoqing, Beesley, Jonathan, Gronwald, Jacek, Fasching, Peter A., Chang-Claude, Jenny, Goodman, Marc T., Chenevix-Trench, Georgia, Berchuck, Andrew, Pearce, Leigh C., Whittemore, Alice S., Menon, Usha, Pharoah, Paul D.P., Gayther, Simon A., and Ramus, Susan J.
- Published
- 2011
- Full Text
- View/download PDF
6. Blood arsenic levels and the risk of familial breast cancer in Poland
- Author
-
Marciniak, Wojciech, primary, Derkacz, Róża, additional, Muszyńska, Magdalena, additional, Baszuk, Piotr, additional, Gronwald, Jacek, additional, Huzarski, Tomasz, additional, Cybulski, Cezary, additional, Jakubowska, Anna, additional, Falco, Michał, additional, Dębniak, Tadeusz, additional, Lener, Marcin, additional, Oszurek, Oleg, additional, Pullella, Katherine, additional, Kotsopoulos, Joanne, additional, Sun, Ping, additional, Narod, Steven A., additional, and Lubiński, Jan, additional
- Published
- 2020
- Full Text
- View/download PDF
7. CHEK2 mutations and HNPCC-related colorectal cancer
- Author
-
Suchy, Janina, Cybulski, Cezary, Wokołorczyk, Dominika, Oszurek, Oleg, Górski, Bohdan, Dębniak, Tadeusz, Jakubowska, Anna, Gronwald, Jacek, Huzarski, Tomasz, Byrski, Tomasz, Dziuba, Ireneusz, Gogacz, Marek, Wiśniowski, Rafał, Wandzel, Piotr, Banaszkiewicz, Zbigniew, Kurzawski, Grzegorz, Kładny, Józef, Narod, Steven A., and Lubiński, Jan
- Published
- 2010
- Full Text
- View/download PDF
8. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer
- Author
-
Złowocka, Elżbieta, Cybulski, Cezary, Górski, Bohdan, Dębniak, Tadeusz, Słojewski, Marcin, Wokołorczyk, Dominika, Serrano-Fernández, Pablo, Matyjasik, Joanna, van de Wetering, Thierry, Sikorski, Andrzej, Scott, Rodney J., and Lubiński, Jan
- Published
- 2008
- Full Text
- View/download PDF
9. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer
- Author
-
Prajzendanc, Karolina, primary, Domagała, Paweł, additional, Hybiak, Jolanta, additional, Ryś, Janusz, additional, Huzarski, Tomasz, additional, Szwiec, Marek, additional, Tomiczek‐Szwiec, Joanna, additional, Redelbach, Wojciech, additional, Sejda, Aleksandra, additional, Gronwald, Jacek, additional, Kluz, Tomasz, additional, Wiśniowski, Rafał, additional, Cybulski, Cezary, additional, Łukomska, Alicja, additional, Białkowska, Katarzyna, additional, Sukiennicki, Grzegorz, additional, Kulczycka, Katarzyna, additional, Narod, Steven A., additional, Wojdacz, Tomasz K., additional, Lubiński, Jan, additional, and Jakubowska, Anna, additional
- Published
- 2019
- Full Text
- View/download PDF
10. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
- Author
-
Wokołorczyk, Dominika, Kluźniak, Wojciech, Huzarski, Tomasz, Gronwald, Jacek, Szymiczek, Agata, Rusak, Bogna, Stempa, Klaudia, Gliniewicz, Katarzyna, Kashyap, Aniruddh, Morawska, Sylwia, Dębniak, Tadeusz, Jakubowska, Anna, Szwiec, Marek, Domagała, Paweł, Lubiński, Jan, Narod, Steven A., Akbari, Mohammad R., and Cybulski, Cezary
- Subjects
BRCA genes ,GENETIC mutation ,GENETIC testing ,PROSTATE cancer ,GRAND strategy (Political science) - Abstract
In designing national strategies for genetic testing, it is important to define the full spectrum of pathogenic mutations in prostate cancer (PCa) susceptibility genes. To investigate the frequency of mutations in PCa susceptibility genes in Polish familial PCa cases and to estimate gene‐related PCa risks and probability of aggressive disease, we analyzed the coding regions of 14 genes by exome sequencing in 390 men with familial prostate cancer and 308 cancer‐free controls. We compared the mutation frequencies between PCa cases and controls. We also compared clinical characteristics of prostate cancers between mutation carriers and noncarriers. Of the 390 PCa cases, 76 men (19.5%) carried a mutation in BRCA1, BRCA2, NBN, ATM, CHEK2, HOXB13, MSH2 or MSH6 genes. No mutations were found in BRIP1, PTEN, TP53, MLH1, PMS2 and SPOP. Significant associations with familial PCa risk were observed for CHEK2, NBN, ATM, and HOXB13. High‐grade (Gleason 8‐10) tumors were seen in 56% of BRCA2, NBN or ATM carriers, compared to 21% of patients who tested negative for mutations in these genes (OR = 4.7, 95% CI 2.0‐10.7, P =.0003). In summary, approximately 20% of familial prostate cancer cases in Poland can be attributed to mutations in eight susceptibility genes. Carriers of mutations in BRCA2, NBN and ATM develop aggressive disease and may benefit from intensified screening and/or chemotherapy. What's new? Genetic susceptibility plays an important role in prostate cancer (PCa). In designing genetic‐testing strategies for PCa screening, it is important to define the full spectrum of pathogenic mutations that increase PCa risk. In this study, the authors found that approximately 20% of familial prostate cancer cases in Poland can be attributed to mutations in eight susceptibility genes. In addition, carriers of mutations in BRCA2, NBN and ATM are more likely to develop aggressive disease. These patients may benefit from intensified screening and/or chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer.
- Author
-
Prajzendanc, Karolina, Domagała, Paweł, Hybiak, Jolanta, Ryś, Janusz, Huzarski, Tomasz, Szwiec, Marek, Tomiczek‐Szwiec, Joanna, Redelbach, Wojciech, Sejda, Aleksandra, Gronwald, Jacek, Kluz, Tomasz, Wiśniowski, Rafał, Cybulski, Cezary, Łukomska, Alicja, Białkowska, Katarzyna, Sukiennicki, Grzegorz, Kulczycka, Katarzyna, Narod, Steven A., Wojdacz, Tomasz K., and Lubiński, Jan
- Subjects
METHYLATION ,BRCA genes ,DNA methylation ,BLOOD cells ,BREAST cancer ,TRIPLE-negative breast cancer - Abstract
Methylation of the promoter of the BRCA1 gene in DNA derived from peripheral blood cells is a possible risk factor for breast cancer. It is not clear if this association is restricted to certain types of breast cancer or is a general phenomenon. We evaluated BRCA1 methylation status in peripheral blood cells from 942 breast cancer patients and from 500 controls. We also assessed methylation status in 262 paraffin‐embedded breast cancer tissues. Methylation status was assessed using methylation‐sensitive high‐resolution melting and was categorized as positive or negative. BRCA1 methylation in peripheral blood cells was strongly associated with the risk of triple‐negative breast cancer (TNBC) (odds ratio [OR] 4.70; 95% confidence interval [CI]: 3.13–7.07; p < 0.001), but not of estrogen‐receptor positive breast cancer (OR 0.80; 95% CI: 0.46–1.42; p = 0.46). Methylation was also overrepresented among patients with high‐grade cancers (OR 4.53; 95% CI: 2.91–7.05; p < 0.001) and medullary cancers (OR 3.08; 95% CI: 1.38–6.88; p = 0.006). Moreover, we detected a significant concordance of BRCA1 promoter methylation in peripheral blood and paired tumor tissue (p < 0.001). We found that BRCA1 promoter methylation in peripheral blood cells is associated with approximately five times greater risk of TNBC. We propose that BRCA1 methylation in blood‐derived DNA could be a novel biomarker of increased breast cancer susceptibility, in particular for triple‐negative tumors. What's new? BRCA1/2 gene mutations are known risk factors for breast cancer, but how DNA methylation of the BRCA gene promoters, especially in peripheral blood cells, is correlated with breast cancer risk is less clear. Here the authors find that BRCA1 promoter methylation in blood‐derived DNA is associated with ~5‐fold increased risk for triple‐negative breast cancer, underscoring its relevance as a biomarker for this treatment‐resistant form of breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. The spectrum of mutations predisposing to familial breast cancer in Poland.
- Author
-
Cybulski, Cezary, Kluźniak, Wojciech, Huzarski, Tomasz, Wokołorczyk, Dominika, Kashyap, Aniruddh, Rusak, Bogna, Stempa, Klaudia, Gronwald, Jacek, Szymiczek, Agata, Bagherzadeh, Maryam, Jakubowska, Anna, Dębniak, Tadeusz, Lener, Marcin, Rudnicka, Helena, Szwiec, Marek, Jarkiewicz‐Tretyn, Joanna, Stawicka, Małgorzata, Domagała, Paweł, Narod, Steven A., and Lubiński, Jan
- Subjects
HEREDITARY cancer syndromes ,BREAST cancer ,BRCA genes ,CANCER susceptibility ,CANCER genes ,GENETIC testing - Abstract
To optimize genetic testing, it is necessary to establish the spectrum of breast cancer‐predisposing mutations in particular ethnic groups. We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes. Additionally, we compared the frequency of candidate pathogenic variants in breast cancer cases and controls. Germline mutations were detected in 512 of 1,018 probands with breast cancer (50.3%), including BRCA1/2 mutations detected in 420 families and non‐BRCA mutations seen in 92 families. Thirteen BRCA1/2 founder mutations represented 84% of all BRCA1/2‐positive cases. Seven founder mutations of CHEK2, PALB2, NBN and RECQL represented 73% of all non‐BRCA‐positive cases. Odds ratios for hereditary breast cancer were 87.6 for BRCA1, 15.4 for PALB2, 7.2 for CHEK2, 2.8 for NBN and 15.8 for RECQL. Odds ratios for XRCC2, BLM and BARD1 were below 1.3. In summary, we found that 20 founder mutations in six genes (BRCA1/2, CHEK2, PALB2, NBN and RECQL) are responsible for 82% of Polish hereditary breast cancer families. A simple test for these 20 mutations will facilitate genetic testing for breast cancer susceptibility in Poland. It may also facilitate genetic testing for breast cancer susceptibility in other Slavic populations and women of Slavic descent worldwide. What's new? Poland is a genetically homogeneous population similar to Iceland, currently designing national policies for genetic testing. To define the range of pathogenic mutations, the authors conducted a large analysis of breast cancer susceptibility genes, defining pathogenic mutations in 50.3% families with hereditary breast cancer. They identified 20 distinct founder mutations in six genes that were responsible for more than 80% of all detected mutations; these 20 mutations could be combined in a single genetic test of breast cancer susceptibility in Polish women. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Serum 25(OH)D concentration, common variants of theVDRgene and lung cancer occurrence
- Author
-
Gromowski, Tomasz, primary, Gapska, Paulina, additional, Scott, Rodney J., additional, Kąklewski, Krzysztof, additional, Marciniak, Wojciech, additional, Durda, Katarzyna, additional, Lener, Marcin, additional, Górski, Bohdan, additional, Cybulski, Cezary, additional, Sukiennicki, Grzegorz, additional, Kaczmarek, Katarzyna, additional, Jaworska-Bieniek, Katarzyna, additional, Paszkowska-Szczur, Katarzyna, additional, Waloszczyk, Piotr, additional, Lubiński, Jan, additional, and Dębniak, Tadeusz, additional
- Published
- 2017
- Full Text
- View/download PDF
14. CHEK2mutations and the risk of papillary thyroid cancer
- Author
-
Siołek, Monika, primary, Cybulski, Cezary, additional, Gąsior-Perczak, Danuta, additional, Kowalik, Artur, additional, Kozak-Klonowska, Beata, additional, Kowalska, Aldona, additional, Chłopek, Małgorzata, additional, Kluźniak, Wojciech, additional, Wokołorczyk, Dominika, additional, Pałyga, Iwona, additional, Walczyk, Agnieszka, additional, Lizis-Kolus, Katarzyna, additional, Sun, Ping, additional, Lubiński, Jan, additional, Narod, Steven A., additional, and Góźdż, Stanisław, additional
- Published
- 2015
- Full Text
- View/download PDF
15. Serum 25(OH)D concentration, common variants of the VDR gene and lung cancer occurrence.
- Author
-
Gromowski, Tomasz, Gapska, Paulina, Scott, Rodney J., Kąklewski, Krzysztof, Marciniak, Wojciech, Durda, Katarzyna, Lener, Marcin, Górski, Bohdan, Cybulski, Cezary, Sukiennicki, Grzegorz, Kaczmarek, Katarzyna, Jaworska‐Bieniek, Katarzyna, Paszkowska‐Szczur, Katarzyna, Waloszczyk, Piotr, Lubiński, Jan, and Dębniak, Tadeusz
- Abstract
The first aim of our study was to examine the association between common variants in VDR [rs2228570 ( FokI), rs1544410 ( BsmI), rs7975232 ( ApaI), rs731236 ( TaqI) and rs11568820 ( Cdx2)] and lung cancer risk in the Polish population. Genotyping and statistical analysis which included Chi-square test with Yates correction and haplotype frequency analysis were performed on a series of 840 consecutively collected lung cancer patients and 920 healthy controls. The second aim was to evaluate the link between serum 25(OH)D concentration and the number of lung cancers in a subgroup of 200 patients. A separate control group that consisted of 400 matched (by age, sex, smoking habits and the season of blood collection) healthy individuals was used to avoid posterior adjustment on the matched variables. Statistical analysis with the use of Chi-square test with Yates was performed. We found no statistically significant difference in the distribution of the allels of studied VDR variants among cases and controls. A statistically significant over-representation of VDR haplotypes: rs731236_A + rs1544410_T [odds ratio (OR) = 2.43, 95% confidence interval (CI) = 1.11-5.32, p < 0.001], rs731236_G + rs1544410_T (OR = 1.54, 95% CI = 1.31-1.81, p < 0.001) and rs731236_G + rs1544410_C (OR = 0.04, 95% CI = 0.03-0.07, p < 0.001) was detected. We found a tendency toward an increased number of lung cancers among individuals with low serum levels of 25(OH)D. To answer the question, whether VDR can be regarded as lung cancer susceptibility gene and low 25(OH)D serum levels is associated with lung cancer occurrences, additional, multicenter study needs to be performed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Germline mutations in theCHEK2 kinase gene are associated with an increased risk of bladder cancer
- Author
-
Złowocka, Elżbieta, primary, Cybulski, Cezary, additional, Górski, Bohdan, additional, Dębniak, Tadeusz, additional, Słojewski, Marcin, additional, Wokołorczyk, Dominika, additional, Serrano-Fernández, Pablo, additional, Matyjasik, Joanna, additional, van de Wetering, Thierry, additional, Sikorski, Andrzej, additional, Scott, Rodney J., additional, and Lubiński, Jan, additional
- Published
- 2007
- Full Text
- View/download PDF
17. CHEK 2 mutations and the risk of papillary thyroid cancer.
- Author
-
Siołek, Monika, Cybulski, Cezary, Gąsior‐Perczak, Danuta, Kowalik, Artur, Kozak‐Klonowska, Beata, Kowalska, Aldona, Chłopek, Małgorzata, Kluźniak, Wojciech, Wokołorczyk, Dominika, Pałyga, Iwona, Walczyk, Agnieszka, Lizis‐Kolus, Katarzyna, Sun, Ping, Lubiński, Jan, Narod, Steven A., and Góźdż, Stanisław
- Abstract
Mutations in the cell cycle checkpoint kinase 2 ( CHEK2) tumor suppressor gene are associated with multi-organ cancer susceptibility including cancers of the breast and prostate. A genetic association between thyroid and breast cancer has been suggested, however little is known about the determinants of this association. To characterize the association of CHEK2 mutations with thyroid cancer, we genotyped 468 unselected patients with papillary thyroid cancer and 468 (matched) cancer-free controls for four founder mutations of CHEK2 ( 1100delC, IVS2 + 1G>A, del5395 and I157T). We compared the family histories reported by patients with a CHEK2 mutation to those of non-carriers. A CHEK2 mutation was seen in 73 of 468 (15.6%) unselected patients with papillary thyroid cancer, compared to 28 of 460 (6.0%) age- and sex-matched controls (OR 3.3; p < 0.0001). A truncating mutation ( IVS2 + 1G>A, 1100delC or del5395) was associated with a higher risk of thyroid cancer (OR = 5.7; p = 0.006), than was the missense mutation I157T (OR = 2.8; p = 0.0001). CHEK2 mutation carriers reported a family history of breast cancer 2.2 times more commonly than non-carriers (16.4% vs.8.1%; p = 0.05). A CHEK2 mutation was found in seven of 11 women (63%) with multiple primary cancers of the breast and thyroid (OR = 10; p = 0.0004). These results suggest that CHEK2 mutations predispose to thyroid cancer, familial aggregations of breast and thyroid cancer and to double primary cancers of the breast and thyroid. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization
- Author
-
Gronwald, Jacek, primary, Jauch, Anna, additional, Cybulski, Cezary, additional, Schoell, Brigitte, additional, Böhm‐Steuer, Barbara, additional, Lener, Marcin, additional, Grabowska, Ewa, additional, Górski, Bohdan, additional, Jakubowska, Anna, additional, Domagała, Wenancjusz, additional, Chosia, Maria, additional, Scott, Rodney J., additional, and Lubiński, Jan, additional
- Published
- 2004
- Full Text
- View/download PDF
19. A high proportion of founderBRCA1mutations in Polish breast cancer families
- Author
-
Górski, Bohdan, primary, Jakubowska, Anna, additional, Huzarski, Tomasz, additional, Byrski, Tomasz, additional, Gronwald, Jacek, additional, Grzybowska, Ewa, additional, Mackiewicz, Andrzej, additional, Stawicka, Malgorzata, additional, Bębenek, Marek, additional, Sorokin, Dagmara, additional, Fiszer-Maliszewska, Łucja, additional, Haus, Olga, additional, Janiszewska, Hanna, additional, Niepsuj, Stanisław, additional, Góźdź, Stanisław, additional, Zaremba, Lech, additional, Posmyk, Michał, additional, Płużańska, Maria, additional, Kilar, Ewa, additional, Czudowska, Dorota, additional, Waśko, Bernard, additional, Miturski, Roman, additional, Kowalczyk, Jerzy R., additional, Urbański, Krzysztof, additional, Szwiec, Marek, additional, Koc, Jan, additional, Dębniak, Bogusław, additional, Rozmiarek, Andrzej, additional, Dębniak, Tadeusz, additional, Cybulski, Cezary, additional, Kowalska, Elzbieta, additional, Tołoczko-Grabarek, Aleksandra, additional, Zajączek, Stanisław, additional, Menkiszak, Janusz, additional, Mędrek, Krzysztof, additional, Masojć, Bartłomiej, additional, Mierzejewski, Marek, additional, Narod, Steven Alexander, additional, and Lubiński, Jan, additional
- Published
- 2004
- Full Text
- View/download PDF
20. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer
- Author
-
Dębniak, Tadeusz, primary, Górski, Bohdan, additional, Scott, Rodney J., additional, Cybulski, Cezary, additional, Mędrek, Krzysztof, additional, Zowocka, Elzbieta, additional, Kurzawski, Grzegorz, additional, Dębniak, Boguslaw, additional, Kadny, Józef, additional, Bielecka‐Grzela, Stanislawa, additional, Maleszka, Romuald, additional, and Lubiński, Jan, additional
- Published
- 2004
- Full Text
- View/download PDF
21. Hereditary ovarian cancer in Poland
- Author
-
Menkiszak, Janusz, primary, Gronwald, Jacek, additional, Górski, Bohdan, additional, Jakubowska, Anna, additional, Huzarski, Tomasz, additional, Byrski, Tomasz, additional, Foszczyńska‐Kłoda, Małgorzata, additional, Haus, Olga, additional, Janiszewska, Hanna, additional, Perkowska, Magdalena, additional, Brożek, Izabela, additional, Grzybowska, Ewa, additional, Zientek, Helena, additional, Góźdź, Stanisław, additional, Kozak‐Klonowska, Beata, additional, Urbański, Krzysztof, additional, Miturski, Roman, additional, Kowalczyk, Jerzy, additional, Plużańska, Anna, additional, Niepsuj, Stanisław, additional, Koc, Jan, additional, Szwiec, Marek, additional, Drosik, Kazimierz, additional, Mackiewicz, Andrzej, additional, Lamperska, Katarzyna, additional, Stróżyk, Elwira, additional, Godlewski, Dariusz, additional, Stawicka, Małgorzata, additional, Waśko, Bernard, additional, Bebenek, Marek, additional, Rozmiarek, Andrzej, additional, Rzepka‐Górska, Izabella, additional, Narod, Steven A., additional, and Lubiński, Jan, additional
- Published
- 2003
- Full Text
- View/download PDF
22. Germline 657del5 mutation in the NBS1 gene in breast cancer patients
- Author
-
Górski, Bohdan, primary, Dębniak, Tadeusz, additional, Masojć, Bartlomiej, additional, Mierzejewski, Marek, additional, Mędrek, Krzysztof, additional, Cybulski, Cezary, additional, Jakubowska, Anna, additional, Kurzawski, Grzegorz, additional, Chosia, Maria, additional, Scott, Rodney, additional, and Lubiński, Jan, additional
- Published
- 2003
- Full Text
- View/download PDF
23. Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization.
- Author
-
Gronwald, Jacek, Jauch, Anna, Cybulski, Cezary, Schoell, Brigitte, Böhm-Steuer, Barbara, Lener, Marcin, Grabowska, Ewa, Górski, Bohdan, Jakubowska, Anna, Domagała, Wenancjusz, Chosia, Maria, Scott, Rodney J., and Lubiński, Jan
- Published
- 2005
- Full Text
- View/download PDF
24. A high proportion of founder BRCA1 mutations in Polish breast cancer families.
- Author
-
Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska Ł, Haus O, Janiszewska H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płuzańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, Kowalska E, Tołoczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojć B, Mierzejewski M, Narod SA, and Lubiński J
- Subjects
- Adult, Family Health, Female, Genes, BRCA2, Humans, Middle Aged, Ovarian Neoplasms genetics, Poland, Breast Neoplasms genetics, Founder Effect, Genes, BRCA1, Mutation
- Abstract
Three mutations in BRCA1 (5382insC, C61G and 4153delA) are common in Poland and account for the majority of mutations identified to date in Polish breast and breast-ovarian cancer families. It is not known, however, to what extent these 3 founder mutations account for all of the BRCA mutations distributed throughout the country. This question has important implications for health policy and the design of epidemiologic studies. To establish the relative contributions of founder and nonfounder BRCA mutations, we established the entire spectrum of BRCA1 and BRCA2 mutations in a large set of breast-ovarian cancer families with origins in all regions of Poland. We sequenced the entire coding regions of the BRCA1 and BRCA2 genes in 100 Polish families with 3 or more cases of breast cancer and in 100 families with cases of both breast and ovarian cancer. A mutation in BRCA1 or BRCA2 was detected in 66% of breast cancer families and in 63% of breast-ovarian cancer families. Of 129 mutations, 122 (94.6%) were in BRCA1 and 7 (5.4%) were in BRCA2. Of the 122 families with BRCA1 mutations, 119 (97.5%) had a recurrent mutation (i.e., one that was seen in at least 2 families). In particular, 111 families (91.0%) carried one of the 3 common founder mutations. The mutation spectrum was not different between families with and without ovarian cancer. These findings suggest that a rapid and inexpensive assay directed at identifying the 3 common founder mutations will have a sensitivity of 86% compared to a much more costly and labor-intensive full-sequence analysis of both genes. This rapid test will facilitate large-scale national epidemiologic and clinical studies of hereditary breast cancer, potentially including studies of chemoprevention., (Copyright 2004 Wiley-Liss, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.